LU76117A1 - - Google Patents

Info

Publication number
LU76117A1
LU76117A1 LU76117A LU76117A LU76117A1 LU 76117 A1 LU76117 A1 LU 76117A1 LU 76117 A LU76117 A LU 76117A LU 76117 A LU76117 A LU 76117A LU 76117 A1 LU76117 A1 LU 76117A1
Authority
LU
Luxembourg
Application number
LU76117A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9162099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU76117(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of LU76117A1 publication Critical patent/LU76117A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU76117A 1975-11-06 1976-11-03 LU76117A1 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533899A FR2330383A1 (fr) 1975-11-06 1975-11-06 Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment

Publications (1)

Publication Number Publication Date
LU76117A1 true LU76117A1 (en:Method) 1978-07-10

Family

ID=9162099

Family Applications (1)

Application Number Title Priority Date Filing Date
LU76117A LU76117A1 (en:Method) 1975-11-06 1976-11-03

Country Status (24)

Country Link
US (2) US4252984A (en:Method)
JP (1) JPS5848543B2 (en:Method)
AR (1) AR214303A1 (en:Method)
AT (1) AT344683B (en:Method)
AU (1) AU501581B2 (en:Method)
BE (1) BE847801A (en:Method)
CA (1) CA1072981A (en:Method)
CH (1) CH602582A5 (en:Method)
DE (1) DE2649605C3 (en:Method)
DK (1) DK145119C (en:Method)
ES (1) ES452920A1 (en:Method)
FI (1) FI62829C (en:Method)
FR (1) FR2330383A1 (en:Method)
GB (1) GB1515978A (en:Method)
GR (1) GR61363B (en:Method)
IE (1) IE43645B1 (en:Method)
IL (1) IL50814A (en:Method)
LU (1) LU76117A1 (en:Method)
NL (1) NL179051C (en:Method)
NO (1) NO142034C (en:Method)
NZ (1) NZ182498A (en:Method)
PT (1) PT65780B (en:Method)
SE (1) SE433208B (en:Method)
ZA (1) ZA766338B (en:Method)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2409980A1 (fr) * 1977-11-24 1979-06-22 Synthelabo Ethers de phenols et leur application en therapeutique
IT1147311B (it) * 1980-02-13 1986-11-19 Stabil Bioterapico Farmachim Eteri basici di 4-idrossi-benzofenoni con attivita' quali agenti betabloccanti e relativi procedimento di preparazione
ZW9881A1 (en) * 1980-06-02 1981-12-23 Hoffmann La Roche Substituted phenoxyaminopropanol derivatives
DE3125870C2 (de) * 1980-07-09 1994-09-15 William John Louis 3-Aminopropoxyphenyl Derivate, ihre Herstellung und sie enthaltende Arzneimittel
CH643527A5 (en) * 1980-10-24 1984-06-15 Ciba Geigy Ag Process for the preparation of 1-alkylamino-3-(4-(2-lower alkoxy-ethyl)phenoxy)-2-propanols
FI76551C (fi) 1980-11-06 1988-11-10 Sandoz Ag Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-aminopropoxifenylderivat.
JPS57108047A (en) * 1980-11-06 1982-07-05 Sandoz Ag 3-aminopropoxyphenyl derivative, manufacture and pharmaceutical composition containing same
US5347050A (en) * 1980-11-06 1994-09-13 Richard Berthold 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
FR2512443A1 (fr) * 1981-09-10 1983-03-11 Synthelabo Derives de phenoxy-3 propanol-2, leur preparation et leur application en therapeutique
DE3151201A1 (de) * 1981-12-23 1983-07-28 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte
US4450172A (en) * 1982-03-10 1984-05-22 E. I. Du Pont De Nemours And Company Antihypertensive polyhalohydroxyisopropyl phenylalka(e)noic acid esters of alkylaminohydroxypropyloxyphenylalkyl alcohols
FR2536390B1 (fr) * 1982-11-22 1986-03-21 Synthelabo Isomere s du betaxolol, sa preparation et son application en therapeutique
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
NZ211815A (en) * 1984-05-15 1988-11-29 Warner Lambert Co Preparation of 1-((3,4-dimethoxyphenethyl)amino)-3- (3-tolyloxy)-2-propanol
GB8412864D0 (en) * 1984-05-19 1984-06-27 Smith Kline French Lab Chemical compounds
US5554367A (en) * 1984-10-31 1996-09-10 Alcon Laboratories, Inc. Compositions for treatment of glaucoma
ES8609190A1 (es) * 1985-02-07 1986-07-16 Pharma Investi S A Un procedimiento para preparar eteres fenolicos
US5095151A (en) * 1985-05-21 1992-03-10 American Home Products Corporation Preparation of propranolol hydrochloride macrocrystals
EP0252007A3 (en) * 1986-06-28 1989-07-05 Ciba-Geigy Ag 2-propanol derivatives as corrosion inhibitors
US4694022A (en) * 1986-12-24 1987-09-15 Alcon Laboratories, Inc. Fatty acid salts of betaxolol useful in the treatment of glaucoma
EP0300290B1 (de) * 1987-07-21 1991-12-18 F. Hoffmann-La Roche Ag Phenoxypropanolamine
FR2672594B1 (fr) * 1991-02-08 1994-07-01 Synthelabo Derives d'ethers de phenols, leur preparation et leur application en therapeutique.
EP0937030B1 (en) * 1995-10-10 2004-03-31 William John Louis 3-amino-propoxyphenyl derivatives (i)
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
US5942633A (en) * 1996-06-19 1999-08-24 Abbott Laboratories Process for the selective alkylation of betaxolol intermediates
US5731463A (en) * 1996-09-23 1998-03-24 Abbott Laboratories Selective alkylation of an alcohol substituted phenol compound
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
US6258350B1 (en) 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
DE60006584T2 (de) * 1999-11-30 2004-09-30 Alcon, Inc. Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
DE60120982T2 (de) * 2000-07-27 2007-02-08 Pharmacia Corp. Kombinationstherapie mit epoxy-steroidalem Aldosteronantagonist und beta-adrenergischem Antagonist zur Behandlung von kongestivem Herzversagen
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
HRP20050163A2 (en) 2002-08-19 2005-06-30 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
AU2004242777B2 (en) * 2003-05-30 2011-05-12 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as HMG-Co inhibitors
CN1300079C (zh) * 2004-12-03 2007-02-14 南京大学 合成4－[2－(环丙基甲氧基)乙基]苯酚的新工艺
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CA2663377A1 (en) 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008105442A1 (ja) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド誘導体
US9782488B2 (en) 2007-03-12 2017-10-10 Nektar Therapeutics Oligomer-beta blocker conjugates
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
JP2009040769A (ja) * 2008-07-09 2009-02-26 William John Louis ３−アミノ−プロポキシフェニル誘導体（ｉ）
CN104208718B (zh) 2009-02-20 2017-12-29 2-Bbb医疗股份有限公司 基于谷胱甘肽的药物递送系统
KR20190116576A (ko) 2009-05-06 2019-10-14 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
HK1213886A1 (zh) 2013-04-17 2016-07-15 辉瑞大药厂 用於治療心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
MX2021008533A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT325023B (de) * 1935-11-15 1975-09-25 Boehringer Sohn Ingelheim Verfahren zur herstellung von neuen racemischen oder optisch aktiven n,n'- bis - (3 - subst. phenoxy -2- hydroxy -1- propyl) - alfa, omega - diaminoalkanen sowie deren säureadditionssalzen
GB1078852A (en) * 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
CA956632A (en) * 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
SE372762B (en:Method) * 1969-05-21 1975-01-13 Haessle Ab
US3712890A (en) * 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
SE354851B (en:Method) * 1970-02-18 1973-03-26 Haessle Ab
GB1458392A (en) * 1973-11-09 1976-12-15 Ici Ltd Optically-active 1-aryloxy-2,3-epoxypropane derivatives

Also Published As

Publication number Publication date
JPS5285146A (en) 1977-07-15
AU501581B2 (en) 1979-06-21
NZ182498A (en) 1978-04-03
ES452920A1 (es) 1977-11-01
FI62829B (fi) 1982-11-30
CH602582A5 (en:Method) 1978-07-31
IE43645L (en) 1977-05-06
BE847801A (fr) 1977-02-14
NO142034C (no) 1980-06-18
DE2649605B2 (de) 1980-07-10
DE2649605C3 (de) 1981-04-02
ATA812076A (de) 1977-12-15
AU1925976A (en) 1978-05-11
US4311708A (en) 1982-01-19
JPS5848543B2 (ja) 1983-10-28
ZA766338B (en) 1977-10-26
AT344683B (de) 1978-08-10
IL50814A (en) 1979-11-30
NL179051C (nl) 1986-07-01
IL50814A0 (en) 1977-01-31
SE433208B (sv) 1984-05-14
DE2649605A1 (de) 1977-05-18
FI763132A7 (en:Method) 1977-05-07
DK495476A (da) 1977-05-07
DK145119C (da) 1983-02-14
PT65780A (fr) 1976-12-01
NO763732L (no) 1977-05-09
SE7612177L (sv) 1977-05-07
IE43645B1 (en) 1981-04-22
FI62829C (fi) 1983-03-10
FR2330383A1 (fr) 1977-06-03
GR61363B (en) 1978-10-30
AR214303A1 (es) 1979-05-31
FR2330383B1 (en:Method) 1979-09-21
PT65780B (fr) 1978-05-10
DK145119B (da) 1982-09-06
NL7612123A (nl) 1977-05-10
GB1515978A (en) 1978-06-28
NO142034B (no) 1980-03-10
NL179051B (nl) 1986-02-03
US4252984A (en) 1981-02-24
CA1072981A (en) 1980-03-04

Similar Documents

Publication Publication Date Title
FR2330383B1 (en:Method)
FR2310515B1 (en:Method)
JPS573752B2 (en:Method)
JPS5228966B2 (en:Method)
JPS565110Y2 (en:Method)
JPS51114852U (en:Method)
FI750868A7 (en:Method)
AU481964A (en:Method)
CH596706A5 (en:Method)
CH1272275A4 (en:Method)
BG23058A1 (en:Method)
CH600561A5 (en:Method)
BG22943A1 (en:Method)
BG22729A1 (en:Method)
BG22440A1 (en:Method)
CH51575A4 (en:Method)
BG22254A1 (en:Method)
BG22130A1 (en:Method)
CH605328A5 (en:Method)
BG21162A1 (en:Method)
CH595059A5 (en:Method)
CH594156A5 (en:Method)
CH595806A5 (en:Method)
CH596819A5 (en:Method)
CH605210A5 (en:Method)